Oxymetazoline (nasal): Drug information

For additional information see "Oxymetazoline (nasal): Patient drug information" and "Oxymetazoline (nasal): Pediatric drug information"

For abbreviations, symbols, and age group definitions show table

Brand Names: US

12 Hour Decongestant [OTC];
12 Hour Nasal Decongestant [OTC] [DSC];
12 Hour Nasal Relief Spray [OTC];
12 Hour Nasal Spray [OTC];
Afrin 12 Hour [OTC] [DSC];
Afrin Menthol Spray [OTC] [DSC];
Afrin Nasal Spray [OTC] [DSC];
Afrin NoDrip Extra Moisture [OTC];
Afrin NoDrip Original [OTC] [DSC];
Afrin NoDrip Sinus [OTC];
Dristan Spray [OTC] [DSC];
FT Nasal Spray [OTC];
Long Lasting Nasal Spray [OTC];
Mucinex Childrens Stuffy Nose [OTC] [DSC];
Mucinex Sinus-Max Clear & Cool [OTC];
Mucinex Sinus-Max Sinus/Allrgy [OTC];
Nasal Decongestant Spray [OTC];
Nasal Spray Max Strength [OTC];
QlearQuil [OTC];
Vicks Sinex 12 Hour Decongest [OTC];
Vicks Sinex Moisturizing [OTC];
Vicks Sinex Severe Decongest [OTC]

Pharmacologic Category

Adrenergic Agonist Agent;
Decongestant;
Imidazoline Derivative

Dosing: Adult

Nasal congestion

Nasal congestion: Intranasal: Instill 2 to 3 sprays into each nostril twice daily (maximum dose: 2 doses/24 hours).

Duration: Generally limit to 3 to 5 days of consecutive use due to risk of rhinitis medicamentosa (Ref). In patients with persistent symptoms despite use of first-line therapies, some guidelines suggest oxymetazoline may be offered in combination with an intranasal corticosteroid for up to 4 weeks with low risk of rhinitis medicamentosa (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in manufacturer’s labeling.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in manufacturer’s labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Oxymetazoline (nasal): Pediatric drug information")

Dosage guidance:

Safety: Oxymetazoline should be administered with the patient and spray bottle in the upright position; administration to a patient in the supine position requires the spray bottle to be inverted resulting in significantly higher doses, increasing the risk of adverse effects and overdose (Ref).

Dosage form information: Nasal solution is available in 2 concentrations (0.025% solution and 0.05% solution); take precautions to verify product selection and avoid confusion between the different concentrations.

Nasal congestion

Nasal congestion: Note: Therapy should not exceed 3 days.

Children 2 to <6 years: 0.025% solution: Intranasal: Instill 2 to 3 sprays into each nostril twice daily as needed; doses should be separated by 10 to 12 hours; maximum daily dose: 2 doses/24 hours.

Children ≥6 years and Adolescents: 0.05% solution: Intranasal: Instill 2 to 3 sprays into each nostril twice daily; doses should be separated by 10 to 12 hours; maximum daily dose: 2 doses/24 hours.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling.

Adverse Reactions

There are no adverse reactions listed in the manufacturer's labeling.

Postmarketing:

Cardiovascular: Acute coronary syndrome (Montastruc 2014), acute myocardial infarction (Rajpal 2014), angina pectoris (Shah 2018), cardiac arrhythmia (Shah 2018), hypertension (including hypertensive crisis) (Shah 2018, Loewen 2004), hypotension (Shah 2018), palpitations (Loewen 2004), syncope (Shah 2018)

Nervous system: Cerebrovascular accident (Cantu 2003), headache (including severe headache [thunderclap]) (Loewen 2004), subarachnoid hemorrhage (Cantu 2003)

Contraindications

OTC labeling: When used for self-medication, do not use for more than 3 days.

Warnings/Precautions

Concerns related to adverse effects:

• Local nasal effects: Temporary discomfort such as burning, stinging, sneezing, or an increased nasal discharge may occur.

• Rebound nasal congestion: Frequent or prolonged use may cause nasal congestion to recur or worsen.

Disease-related concerns:

• Cardiovascular disease: Use with caution in patients with hypertension or heart disease.

• Diabetes: Use with caution in patients with diabetes mellitus.

• Thyroid disease: Use with caution in patients with thyroid disease.

• Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.

Other warnings/precautions:

• Accidental ingestion: Accidental ingestion by children of over-the-counter (OTC) imidazoline-derivative eye drops and nasal sprays may result in serious harm. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who had ingested even small amounts (eg, 1 to 2 mL). Contact a poison control center and seek emergency medical care immediately for accidental ingestion (FDA Drug Safety Communication 2012).

• Self-medication (OTC use): When used for self-medication (OTC), do not use >3 days; do not exceed recommended dosages; use of this container by more than one person may spread infection.

Warnings: Additional Pediatric Considerations

Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Solution, Nasal, as hydrochloride:

12 Hour Decongestant: 0.05% (30 mL) [contains benzalkonium chloride, edetate (edta) disodium dihydrate, polyethylene glycol (macrogol), propylene glycol]

12 Hour Nasal Decongestant: 0.05% (30 mL [DSC]) [contains benzalkonium chloride, benzyl alcohol, edetate (edta) disodium, polyethylene glycol (macrogol)]

12 Hour Nasal Relief Spray: 0.05% (30 mL)

12 Hour Nasal Spray: 0.05% (30 mL) [contains benzalkonium chloride]

Afrin 12 Hour: 0.05% (30 mL [DSC]) [contains benzalkonium chloride, disodium edta, polyethylene glycol (macrogol), propylene glycol]

Afrin Menthol Spray: 0.05% (15 mL [DSC])

Afrin Nasal Spray: 0.05% (20 mL [DSC]) [contains benzalkonium chloride, disodium edta]

Afrin NoDrip Extra Moisture: 0.05% (15 mL) [contains benzalkonium chloride]

Afrin NoDrip Original: 0.05% (15 mL [DSC]) [contains benzalkonium chloride]

Afrin NoDrip Sinus: 0.05% (15 mL) [contains benzalkonium chloride, menthol]

Dristan Spray: 0.05% (15 mL [DSC]) [contains benzalkonium chloride, disodium edta]

FT Nasal Spray: 0.05% (30 mL) [contains benzalkonium chloride, edetate (edta) disodium]

FT Nasal Spray: 0.05% (30 mL) [contains benzalkonium chloride, edetate (edta) disodium, menthol, polysorbate 80]

FT Nasal Spray: 0.05% (30 mL) [gluten free; contains benzalkonium chloride, benzyl alcohol, edetate (edta) disodium]

Long Lasting Nasal Spray: 0.05% (30 mL) [contains benzalkonium chloride]

Mucinex Childrens Stuffy Nose: 0.05% (22 mL [DSC]) [contains benzalkonium chloride, disodium edta, menthol, polysorbate 80, propylene glycol]

Mucinex Sinus-Max Clear & Cool: 0.05% (22 mL) [contains benzalkonium chloride, edetate (edta) disodium, menthol, polyethylene glycol (macrogol), polysorbate 80, propylene glycol]

Mucinex Sinus-Max Sinus/Allrgy: 0.05% (22 mL) [contains benzalkonium chloride, disodium edta, propylene glycol]

Nasal Decongestant Spray: 0.05% (15 mL [DSC]) [contains benzalkonium chloride, benzyl alcohol, edetate (edta) disodium, propylene glycol]

Nasal Decongestant Spray: 0.05% (15 mL, 30 mL) [contains benzalkonium chloride, edetate (edta) disodium]

Nasal Decongestant Spray: 0.05% (15 mL, 30 mL) [contains benzalkonium chloride, edetate (edta) disodium, polyethylene glycol (macrogol), propylene glycol]

Nasal Spray Max Strength: 0.05% (30 mL) [gluten free; contains benzalkonium chloride, benzyl alcohol, disodium edta]

QlearQuil: 0.05% (15 mL) [contains benzalkonium chloride, disodium edta]

Vicks Sinex 12 Hour Decongest: 0.05% (15 mL) [contains benzalkonium chloride, disodium edta]

Vicks Sinex Moisturizing: 0.05% (15 mL) [contains benzalkonium chloride, benzyl alcohol, edetate (edta) disodium, polysorbate 80]

Vicks Sinex Severe Decongest: 0.05% (15 mL) [contains benzalkonium chloride, benzyl alcohol, edetate (edta) disodium, menthol, polysorbate 80]

Generic: 0.05% (30 mL)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (Giltuss Severe Sinus Nasal)

0.05% (per mL): $0.49

Solution (Mucinex Sinus-Max Clear & Cool Nasal)

0.05% (per mL): $0.44

Solution (Mucinex Sinus-Max Sinus/Allrgy Nasal)

0.05% (per mL): $0.44

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Intranasal: For intranasal use only. Shake well before use (varies by product; also refer to manufacturer’s labeling). Before using for the first time, prime the pump by firmly depressing the rim several times. Keep head upright and insert nozzle into nostril, depress rim firmly, and inhale deeply.

Administration: Pediatric

Intranasal: For intranasal use only. Shake well before use. Before using for the first time, follow directions per labeling for any applicable priming. Keep head upright (do not tilt) during administration. Insert nozzle/applicator into nostril and spray; patient and spray bottle should remain upright; do not administer with patient in the supine position or with spray bottle inverted as that may increase the dose administered, leading to overdose (Ref).

Use: Labeled Indications

Nasal congestion: Temporary relief of nasal congestion (due to a cold, hay fever, or other upper respiratory allergies) and sinus congestion/pressure.

Use: Off-Label: Adult

Topical vasoconstriction in nasal procedures

Medication Safety Issues

Sound-alike/look-alike issues:

Oxymetazoline may be confused with oxymetholone

Afrin may be confused with aspirin

Afrin (oxymetazoline) may be confused with Afrin (saline)

Neo-Synephrine (oxymetazoline) may be confused with Neo-Synephrine (phenylephrine, nasal)

Other safety concerns:

Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children ≤5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Atomoxetine: May increase hypertensive effects of Sympathomimetics. Atomoxetine may increase tachycardic effects of Sympathomimetics. Risk C: Monitor

Atropine (Systemic): May increase hypertensive effects of Alpha1-Agonists. Risk C: Monitor

Bornaprine: Sympathomimetics may increase anticholinergic effects of Bornaprine. Risk C: Monitor

Bromocriptine: May increase hypertensive effects of Alpha1-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days. Risk D: Consider Therapy Modification

Cannabinoid-Containing Products: May increase tachycardic effects of Sympathomimetics. Risk C: Monitor

Cocaine (Topical): May increase hypertensive effects of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Risk D: Consider Therapy Modification

Dihydralazine: Sympathomimetics may decrease therapeutic effects of Dihydralazine. Risk C: Monitor

Doxofylline: Sympathomimetics may increase adverse/toxic effects of Doxofylline. Risk C: Monitor

Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May increase vasoconstricting effects of Alpha1-Agonists. Risk X: Avoid

Esketamine (Injection): May increase adverse/toxic effects of Sympathomimetics. Specifically, the risk for elevated heart rate, hypertension, and arrhythmias may be increased. Risk C: Monitor

Esketamine (Nasal): Decongestants (Nasally Administered) may decrease therapeutic effects of Esketamine (Nasal). Management: Patients who require a nasal decongestant on an esketamine dosing day should administer the nasal decongestant at least 1 hour before esketamine. Risk D: Consider Therapy Modification

FentaNYL: Decongestants may decrease serum concentration of FentaNYL. Risk C: Monitor

Guanethidine: May increase hypertensive effects of Sympathomimetics. Guanethidine may increase arrhythmogenic effects of Sympathomimetics. Risk C: Monitor

Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may decrease therapeutic effects of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Risk X: Avoid

Kratom: May increase adverse/toxic effects of Sympathomimetics. Risk X: Avoid

Levothyroxine: May increase therapeutic effects of Sympathomimetics. Sympathomimetics may increase therapeutic effects of Levothyroxine. Levothyroxine may increase adverse/toxic effects of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Risk C: Monitor

Linezolid: May increase hypertensive effects of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid. Risk D: Consider Therapy Modification

Lisuride: May increase hypertensive effects of Alpha1-Agonists. Risk X: Avoid

Metergoline: May increase adverse/toxic effects of Alpha1-Agonists. Risk C: Monitor

Monoamine Oxidase Inhibitors: May increase hypertensive effects of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Risk X: Avoid

Pergolide: May increase hypertensive effects of Alpha1-Agonists. Risk C: Monitor

Solriamfetol: Sympathomimetics may increase hypertensive effects of Solriamfetol. Sympathomimetics may increase tachycardic effects of Solriamfetol. Risk C: Monitor

Sympathomimetics: May increase adverse/toxic effects of Sympathomimetics. Risk C: Monitor

Tedizolid: May increase adverse/toxic effects of Sympathomimetics. Specifically, the risk for increased blood pressure and heart rate may be increased. Risk C: Monitor

Tricyclic Antidepressants: May increase therapeutic effects of Alpha1-Agonists. Tricyclic Antidepressants may decrease therapeutic effects of Alpha1-Agonists. Risk C: Monitor

Zavegepant: Decongestants (Nasally Administered) may decrease serum concentration of Zavegepant. Management: Avoid the concurrent administration of intranasal decongestants with zavegepant. If combined use is unavoidable, intranasal decongestants should be administered at least 1 hour after zavegepant administration. Risk D: Consider Therapy Modification

Pregnancy Considerations

Adverse fetal/neonatal events have been noted in case reports following large doses or extended use of oxymetazoline nasal spray in the first trimester of pregnancy (Baxi 1985; Holm 1985; Menezes 2016). Fetal blood flow was not found to be affected by a one-time dose of oxymetazoline in noncomplicated, third trimester pregnancies (Rayburn 1990).

Decongestants are not recommended for the treatment of rhinitis during pregnancy (BSACI [Scadding 2017]). Use of oxymetazoline nasal spray can be considered if acute relief is needed (Mazzotta 1999).

Breastfeeding Considerations

If a decongestant is needed, nasal preparations may be preferred over systemic agents in nursing women (Anderson 2000).

Mechanism of Action

Stimulates alpha-adrenergic receptors in the arterioles of the nasal mucosa to produce vasoconstriction

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Within 10 minutes (Chua 1989)

Duration: Up to 12 hours (Chua 1989)

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Afrin | Duration | Iliadin | Nasivin | Oxylin | Utabon;
(AR) Argentina: Allerhit spray nasal | Alosol | Isly | Lidil | Lidil Spray | Newclar | Ocurel lc | Oxiler d | Panoxi | Vick sinex;
(AT) Austria: Nasiben sanft | Nasivin | Wick sinex | Wick Sinexaloe;
(AU) Australia: Amcal decongestant | Apohealth decongestant | Blooms the chemist decongestant | Chemists own decongestant | Chemplus decongestant | Colden | Decongestant | Demazin 12 hour relief nasal spray | Dimetapp | Discount drug stores decongestant | Drixine | Hs | Logicin rapid relief | Mendeleev nasal decongestant | O/n | Pharmacy action nasal decongestant | Pharmacy care decongestant | Pharmacy health decongestant nasal spray | Priceline decongestant | Sudafed nasal decongestant | Trust decongestant | Twp nasal decong | Vicks sinex | Wagner health Wagner health Nasal Decongestant | Your pharmacy decongestant;
(BD) Bangladesh: Afrin | Azolin | Congenil | G con | Iliadin | Nasalox | Natazol | Nazolin | Oxydrop | Oxyfast | Oxymet | Oxynex | Rynex | Xylocon | Zoli;
(BE) Belgium: Nesivine | Rhino humex | Vicks sinex;
(BF) Burkina Faso: Aturgyl | Respibien;
(BG) Bulgaria: Afrin | Afrin nd | Nazopass | Resoxym | Vicks sinex aloe and eucaliptus;
(BR) Brazil: Afrin | Aturgyl | Aturgyl nf | Cloridrato de oximetazolina | Desfrin | Freenal | Nasivin | Oxifrin | Oxilin | Rinidal | Rinitin;
(CH) Switzerland: Nasivin;
(CL) Chile: Afrine | Afrine oftalmico | Iliadin | Isly | Oxiler d | Oxilin | Xenius;
(CN) China: Bo fen lin | Da fen lin | Di li tuo | Feng lang | Oxylin | Oxymetazoline;
(CO) Colombia: Afrin | Clarivis | Drixine | Nafazol | Nasivin | Nasivin baby | Nasivin infantil | Openxy | Oxiflash | Oxifrin adulto | Oximetazolina | Oximetazolina clorhidrato | Oximetazolina Hcl | Oximisyn | Rhinofrenol | Wasserfrin;
(CR) Costa Rica: Afrin;
(CZ) Czech Republic: Afrin | Nasivin | Nasivin Sensitive | Oxamet | Sinex | Sinex vicks aloe a eukalyptus;
(DE) Germany: Em-eukal mono | Em-medical | Nasivin | Nasivin ohne Konservierungsstoffe | Nasivin zink | Wick sinex;
(DO) Dominican Republic: Afrin | Afrin Lub | Alcamin | Iliadin | Lidil | Nasin | Oxilina | Respibien | Utabon | Visina LR;
(EC) Ecuador: Afrin | Afrin infantil | Afrin ultra | Ocuclear | Openxy | Oximetazolina Hcl | Oximetazolina hcl mk | Rinex;
(EE) Estonia: Afrin glycerol | Lekonil | Nazol | Wick sinex;
(EG) Egypt: Afrin | Iliadin | Oxymet | Oxymetazoline MUP;
(ES) Spain: Alerfrin | Aurorespir | Corilisina | Cuvenax | Descongestan | Egarone oximetazol | Ilvinax | Interfrin | Lairesp | Nasolina | Nebulicina | Normonasal | Novag rino | Oftinal | Okalrinus | Oximetazolina edigen | Oximetazolina farlline | Oximetazolina tecnimede | Respibien | Respibien Freshmint | Respir | Rinotec | Serranasal | Sinexsensi | Utabon;
(ET) Ethiopia: Nasalox;
(FI) Finland: Drixin | Iliadin;
(FR) France: Aturgyl;
(GB) United Kingdom: Afrazine | Asda nasal decongestant spray | Boots blocked nose relief | Galpharm blocked nose relief | Nasivin | Oxymetazoline | Vicks sinex soother;
(GR) Greece: Ezixin | Ronal | Vicks sinex;
(HK) Hong Kong: Afrin | Duration | Iliadin | Logicin rapid relief | Nasomist | Oxy nase | Respibien | Synus;
(HR) Croatia: Operil | Operil p;
(HU) Hungary: Afrin | Nasivin | Nasivin sanft | Wick sinex avera;
(ID) Indonesia: Afrin | Iliadin | Visine Long Range;
(IE) Ireland: Afrazine | Neilmed Sinufrin | Vicks sinex;
(IL) Israel: Alrin | Rhinoclir | Sinulen;
(IN) India: Blockfree | Codylex nasal | Febrex plus - ns | Lemolate | Maxtra o | Medinoze junior | Naselin | Nasivion | Nazoden | Otrivin-o | Oxylin | Oxymet | Oxyspray | Rhinojet | Rhinoset oxy | Sinarest | Sinoxy | Sudin | Tencol | Vicks sinex | Vilco nasal drops | Xynose | Xynose kit | Zoamet | Zomet;
(IQ) Iraq: Nazordin;
(IR) Iran, Islamic Republic of: Rinozoline;
(IT) Italy: Actifed nasale | Coricidin | Leviorinil | Narielle | Neo borocillina nasale | Ossimetazolina MG | Oxilin | Rino calyptol | Vicks sinex;
(JO) Jordan: Iliadin | Nasivin | Oxazoline;
(JP) Japan: Nasivin;
(KE) Kenya: Iliadin | Iliadin baby nose drops | Iliadin kids nose drops | Nasivin | Nasivion | Nazolin | Oxylin | Utabon adult | Utabon paediatric;
(KR) Korea, Republic of: Cleanb | Green nasal | Otrivin s | Oxyaid | Oxycozal | Oxyzol | Respibien | Siwontachoa | Synus;
(KW) Kuwait: Duration | Iliadin | Nasivin | Utabon;
(LB) Lebanon: Alerjon | Duration | Nasivin | Utabon;
(LT) Lithuania: Afrin | End-oksimetazolin | Exnos | Lekonil | Lekonil p | Nasivin | Nasol | Nazol | Resoxym;
(LU) Luxembourg: Nasivin | Nesivine | Vicks sinex;
(LV) Latvia: Afrin | Afrin Chamomile | Alrin | Lekonil | Lekonil p | Nasivin | Nasol | Nazol | Oxamet | Sinex;
(MA) Morocco: Nasivine;
(MX) Mexico: Afrin | Afrin Lub | Afrin no drip | Afrin no drip cse | Collifrin | Iliadin | Lubyox | Naztril | Ocuclear | Oximetazolina | Oxylin | Ritrila | Virindrez;
(MY) Malaysia: Afrin | Axcel Oxymetazoline | Iliadin | Kotrin | Oxazoline | Oxy nase | Oxymetazoline wintac | Utabon | Xylocon;
(NG) Nigeria: Iliadin baby nose drops | Iliadin decongestant nose spray adults | Iliadin kids nose drops | Kinglion oxymetazoline hydrochloride | Nasic;
(NL) Netherlands: Nasivin | Oxylin | Vicks sinex;
(NO) Norway: Iliadin | Nasiben baby sanft | Nasivin | Rhinox;
(NZ) New Zealand: Apohealth decongestant | At-eze | Dimetapp | Drixine | Mucinex Sinus | Pharmacy health decongestant nasal spray | Priceline decongestant | Sinex | Sudafed nasal decongestant | Trust decongestant | Vicks sinex | Wagner health nasal decongestant | Your pharmacy decongestant;
(PE) Peru: Afrin | Alerjon | Clarivis | Eyeston | Iliadin | Oximetazolina | Oxylin | Respibien | Rinerge | Rinophar | Rynat d | Rynatan d;
(PH) Philippines: Drixine | Iliadin | Nasivin | Nasofix | Nasofree | Oxy nase;
(PK) Pakistan: Naldin | Oxylin | Rinerge;
(PL) Poland: Acatar | Acatar care | Acatar care kids | Acatar control | Afrin | Afrin nd | Nasivin | Nasivin baby | Nasivin classic | Nasivin kids | Nasivin sinex | Nasivin soft | Nosox | Nosox classic | Nosox junior | Oxalin | Oxymetazolin apteo | Resoxym | Vicks sinex aloes i eukaliptus;
(PR) Puerto Rico: Afrin | Afrin All Night No Drip | Afrin childrens | Afrin no drip | Afrin severe congestion | Bausch&Lomb Nasal | Genasal la | Giltuss severe sinus | Mucinex children's stuffy nose | Mucinex sinus max full force | Mucinex sinus max moisture smart | Mucinex sinus max sinus & allergy | Nostrilla | Nostrilla 12 hour nasal decongestant | Ocuclear | Oxymetazoline HCL | Sinufrin | Sudafed om | Sudafed Om Sinus Congestion | Vicks Early Defense;
(PT) Portugal: Alerjon | Bisolspray | Ilvico respir | Nasarox | Nasex | Nasitrim | Nasorhinathiol | Oximetazolina farmoz | Oxylin | Rinerge | Sinexsensi | Zolinol;
(PY) Paraguay: Rimevax | Rinarin;
(QA) Qatar: Nasivin;
(RO) Romania: Afrin;
(RU) Russian Federation: Afrin | Afrin extro | Afrin moisturizing | Fervex nasal | Knoxpray | Lekonil | Nasivin | Nasivin Sensitive | Nazol | Nazol advance | Nazospray | Nesopin | Otrivin express | Oxyfrin | Oxymetazoline | Oxymetazoline akrikhin | Oxymethazoline | Rankof rino | Rinostop | Rinostop extra | Sanorinchik | Sialor Rhino | Vicks active sinex | Vicks sinex;
(SA) Saudi Arabia: Iliadin | Nasivin | Oxylin;
(SE) Sweden: Drixin | Iliadin | Nasin | Nezepro | Nezeril | Nezeril dexpantenol | Vicks sinex;
(SG) Singapore: Afrin | Iliadin | Kotrin | Nazolin | Oxy nase | Vicks sinex;
(SI) Slovenia: Afrin | Nasivin | Nazopass | Operil;
(SK) Slovakia: Afrin | Nasivin;
(SR) Suriname: Visine l.r.;
(TH) Thailand: Feenoze | Iliadin | Metzodin | Nasil | Omelin light | Oxylin | Oxymet | Phindroz | Sifrin nebulizer;
(TN) Tunisia: Aturgyl;
(TR) Turkey: Burazin | Iliadin | Oksinazal | Oxynaz | Rhinfant;
(TW) Taiwan: Anjet j | Berton | Bichanshun | Cortimin | Ephrine | Libiton | Masalax | Nasaton | Nasline | Nasolax | Nazal m | Nezeril | Oxymetazoline | Pitosan | Respibien | Rhinly | Sindecon | Suton-p | Swinin | Win-min | Win-Way;
(UA) Ukraine: Afrin | Loratek | Nasalong kids | Nasivin | Nasivin Sensitive | Nasol | Nasol kids | Nazalong | Nazo | Neosinus | Noxprey | Noxprey active | Noxprey Dytiachyi | Noxprey malyuk | Rhinoxil n | Rinazal extra | Rinazoline | Rint | Sinumax;
(UG) Uganda: Iliadin | Sinarest | Sinarest pd;
(UY) Uruguay: Alergidina | Lidil | Oxiler d | Oxilin;
(VE) Venezuela, Bolivarian Republic of: Afrin | Airex | Airfen | Clarix | Drixine | Nasin | Oximetazolina | Solarsal;
(VN) Viet Nam: Bicol B | Oxacol;
(ZA) South Africa: Allergex | Drinasal paediatric | Drixine | Iliadin | Oxylin | Oxymetazoline | Oxymist | Oxyspray moisturising | Sinustop | Sparkling white | Vicks sinex decon | Zadin;
(ZM) Zambia: Nasivion | Oxy nase

Afrin No Drip Original (oxymetazoline hydrochloride) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; received March 2025.
Afrin Original (oxymetazoline hydrochloride) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC: received August 2019.
Afrin Pump Mist (oxymetazoline hydrochloride) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC: received August 2019.
Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. [PubMed 3960626]
Anderson PO. Decongestants and milk production. J Hum Lact. 2000;16(4):294. [PubMed 11155604]
Baxi LV, Gindoff PR, Pregenzer GJ, et al, "Fetal Heart Rate Changes Following Maternal Administration of a Nasal Decongestant," Am J Obstet Gynecol, 1985, 153(7):799-800. [PubMed 2416220]
Cantu C, Arauz A, Murillo-Bonilla LM, López M, Barinagarrementeria F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003;34(7):1667-1672. doi:10.1161/01.STR.0000075293.45936.FA [PubMed 12791938]
Cartabuke R, Tobias JD, Jatana KR; Section on Anesthesiology and Pain Medicine, Section on Otolaryngology–Head and Neck Surgery. Topical nasal decongestant oxymetazoline: safety considerations for perioperative pediatric use. Pediatrics. 2021;148(5):e2021054271. doi:10.1542/peds.2021-054271 [PubMed 34607935]
Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm. [PubMed 6423951]
Children's Afrin Extra Moisturizing Stuffy Nose Pump Mist (oxymetazoline hydrochloride) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; no date.
Chua SS, Benrimoj SI, Triggs EJ. Pharmacokinetics of non-prescription sympathomimetic agents. Biopharm Drug Dispos. 1989;10(1):1-14. [PubMed 2647163]
Dykewicz MS, Wallace DV, Amrol DJ, et al; Workgroup Contributors. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007 [PubMed 32707227]
Food and Drug Administration. FDA Drug Safety Communication: Serious adverse events from accidental ingestion by children of over-the-counter eye drops and nasal sprays. U.S. Food and Drug Administration. October 25, 2012. Available at http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm. Accessed September 5, 2013.
Higgins TS, Hwang PH, Kingdom TT, Orlandi RR, Stammberger H, Han JK. Systematic review of topical vasoconstrictors in endoscopic sinus surgery. Laryngoscope. 2011;121(2):422-432. doi: 10.1002/lary.21286. [PubMed 21271600]
Holm IA and Clarren SK, "An Unusual Pattern of Malformation Associated With Gestational Exposure to Nasal Spray," J Pediatr, 1985, 106(5):860-1. [PubMed 3998934]
"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313. [PubMed 12534540]
Johns ME, Richtsmeier WJ. Otolaryngology--head and neck surgery. JAMA. 1994;271(21):1698-1700. [PubMed 8182859]
Latham GJ, Jardine DS. Oxymetazoline and hypertensive crisis in a child: can we prevent it? Paediatr Anaesth. 2013;23(10):952-956. doi:10.1111/pan.12192 [PubMed 23679077]
Loewen AH, Hudon ME, Hill MD. Thunderclap headache and reversible segmental cerebral vasoconstriction associated with use of oxymetazoline nasal spray. CMAJ. 2004;171(6):593-594. doi:10.1503/cmaj.1040631 [PubMed 15367461]
Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172. [PubMed 10985636]
Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy. Safety considerations. Drug Saf. 1999;20(4):361‐375. doi:10.2165/00002018-199920040-00005 [PubMed 10230583]
Menezes GA, Araujo Júnior E, Lopes J, Belmonte S, Tonni G⁴, Werner H. Prenatal diagnosis and physical model reconstruction of agnathia-otocephaly with limb deformities (absent ulna, fibula and digits) following maternal exposure to oxymetazoline in the first trimester. J Obstet Gynaecol Res. 2016;42(8):1016-1020. [PubMed 27087030]
Montastruc F, Montastruc G, Taudou MJ, Olivier-Abbal P, Montastruc JL, Bondon-Guitton E. Acute coronary syndrome after nasal spray of oxymetazoline. Chest. 2014;146(6):e214-e215. doi:10.1378/chest.14-1873 [PubMed 25451367]
Mucinex Children's Stuffy Nose Spray (oxymetazoline hydrochloride) [prescribing information]. Parsippany, NJ: Reckitt Benckiser; March 2018.
Mucinex Sinus-Max Sinus & Allergy (oxymetazoline hydrochloride) [prescribing information]. Parsippany, NJ: RB Health (US); received March 2020.
Rayburn WF, Anderson JC, Smith CV, et al, "Uterine and Fetal Doppler Flow Changes From a Single Dose of a Long-Acting Intranasal Decongestant," Obstet Gynecol, 1990, 76(2):180-2. [PubMed 2196495]
Rajpal S, Morris LA, Akkus NI. Non-ST-elevation myocardial infarction with the use of oxymetazoline nasal spray. Rev Port Cardiol. 2014;33(1):51.e1-51.e514. doi:10.1016/j.repc.2013.07.011 [PubMed 24405558]
Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy. 2017;47(7):856‐889. doi:10.1111/cea.12953 [PubMed 30239057]
Seidman MD, Gurgel RK, Lin SY, et al; Guideline Otolaryngology Development Group. AAO-HNSF. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(1)(suppl):S1-S43. doi:10.1177/0194599814561600 [PubMed 25644617]
Shah S, Patel K, Gambhir HS. Oxymetazoline-induced asthma. Am J Ther. 2018;25(6):e681-e682. doi:10.1097/MJT.0000000000000628 [PubMed 28901959]
Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259. [PubMed 19188870]
Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313. [PubMed 7746084]
Tarver CP, Noorily AD, Sakai CS. A comparison of cocaine vs. lidocaine with oxymetazoline for use in nasal procedures. Otolaryngol Head Neck Surg. 1993;109(4):653-659. doi: 10.1177/019459989310900404. [PubMed 8233500]
Vicks Sinex (oxymetazoline hydrochloride) [prescribing information]. Cincinnati, OH: Procter & Gamble; received August 31, 2016.
Vicks Sinex Moisturizing (oxymetazoline hydrochloride) [prescribing information]. Cincinnati, OH: Procter & Gamble; received August 31, 2016.
Vicks Sinex Severe (oxymetazoline hydrochloride) [prescribing information]. Cincinnati, OH: Procter & Gamble; received October 2019.

Topic 9896 Version 417.0

خرید پکیج

Oxymetazoline (nasal): Drug information